Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07467252) titled 'AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT' on March 9.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).

Primary Sponsor: Ministry of Health, Saudi Arabia

Condition: Pulmonary Tuberculosis

Intervention: Drug: Pyrazinamide and Hydroxychloroquine (AI-Optimised)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 2026

Target Sample Size: 200

Countries of Recruitment...